Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating a new approach to radiotherapy for patients with glioblastoma, a common and aggressive brain tumor. This trial aims to determine if focusing radiation treatment more precisely by reducing the usual safety margin can safely decrease side effects and improve quality of life. Despite current treatments involving surgery, radiotherapy, and chemotherapy, survival remains limited and quality of life is often impaired for these patients. The study compares two radiotherapy approaches one with the standard irradiation volume including a 15mm safety margin around the tumor, and another with a reduced 10mm margin to limit the amount of healthy brain tissue exposed. Both groups receive chemoradiotherapy as part of their treatment. This national multicenter trial will randomize patients to either the standard or reduced radiotherapy volume to assess outcomes. Participants will be followed for up to two years with regular assessments of overall survival, neurocognitive function, treatment-related toxicity, quality of life, disease progression, and recurrence patterns. Evaluations include baseline measurements and follow-ups at one month and one year after radiotherapy. Researchers will also monitor use of anti-edema therapy during the study. The total participation duration and study procedures are designed to monitor safety and the impact of the radiation volume on patient well-being.
Actively Recruiting
Researchers are studying women with a recent history of gestational diabetes GDM who have persistent glucose intolerance shortly after giving birth. These women are at high risk of developing type 2 diabetes T2DM, with about half developing it within five years. The study aims to evaluate whether using semaglutide, a long-acting GLP-1 agonist, can reduce the long-term risk of developing T2DM compared to placebo. This study is a phase 3, double-blind, randomized controlled trial conducted in multiple centers. Participants are randomly assigned to receive either semaglutide or a placebo once weekly by injection, alongside lifestyle measures. The semaglutide dose is gradually increased over eight weeks to a maintenance dose of 1 mg per week. The treatment period can last up to three years. After stopping the intervention, participants will undergo a 75g oral glucose tolerance test OGTT 3 to 6 months later. Randomization considers body mass index categories at early postpartum. Throughout the study, participants will have regular assessments including blood tests for glucose, HbA1c, insulin sensitivity, and beta-cell function. Researchers will also measure body weight, body composition, blood pressure, heart rate, lipid profiles, and metabolic syndrome prevalence. Patient-reported outcomes such as quality of life, depression, anxiety, treatment satisfaction, sleep quality, and food security will be collected. Health economic measures and biomarker analyses will also be performed. The primary outcome is the development of type 2 diabetes by 160 weeks, with continued follow-up up to 184 weeks.